LUMEN THERAPEUTICS COMPLETES PORTION OF ITS LT-1951 STUDY

Lumen Therapeutics has completed the Phase I portion of the its Phase I/II clinical trial evaluating LT-1951 as a treatment for the prevention of graft failure following saphenous vein coronary artery bypass graft (CABG) surgery. The objective of this portion of the trial was to assess the safety and tolerability of LT-1951, which is used to treat the excised saphenous vein before grafting. The trial indicated that LT-1951 was well-tolerated under the test conditions. Subjects suffered no drug-related serious adverse events.

Lumen has completed treatment of 20 patients that underwent multiple-vein CABG, and plans to expand the study into a Phase II trial that will include an additional 30 patients. The trial was designed so that each patient received at least one vein graft treated with LT-1951 and at least one graft treated with placebo.